Forma Therapeutics jumps 48% on $1.1B buyout deal with Novo Nordisk

Sep. 01, 2022 8:38 AM ETNovo Nordisk A/S (NVO)NONOFBy: Dulan Lokuwithana, SA News Editor6 Comments

word m and a made with wood building blocks, stock image

Maksim Labkouski

Danish drugmaker Novo Nordisk A/S (NVO) (OTCPK:NONOF) has agreed to acquire Forma Therapeutics (FMTX), a U.S.-based biotech focused on therapies for sickle cell disease (SCD), in an all-cash deal worth $1.1B in equity value, the companies announced Thursday.

Following a brief trading halt, FMTX added 48% in the pre-market while American Depository Shares of NVO traded flat in reaction to news.

Per the terms, NVO will acquire all outstanding shares of FMTX’s common stock for $20 per share in cash, indicating a ~92% premium to the company’s 30-day volume-weighted average price per share. The transaction is expected to close in Q4 2022.

In connection with the deal, R.A. Capital Management, L.P., which holds nearly ~19% of FMTX shares, has agreed to tender its FMTX shares in a tender offer that NVO plans to initiate for the acquisition.

FMTX’s clinical portfolio includes Etavopivat, which is undergoing a global phase 2/3 trial for SCD and a phase 2 trial for transfusion-dependent SCD and thalassemia.

The offer for FMTX comes at a time when company shares have plunged ~44% over the past 12 months, as shown in this graph.

Recommended For You

Comments (6)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.